Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $97.62M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 6.81M
Average 17.46M
Returns on capital
Outlook Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
193.9%
avg -57.6%
ROIC
-2357.6%
avg -424.2%
ROA
-335.9%
avg -234.6%
Analysis
ROE is currently the strongest return metric at 193.9% versus its period average of -57.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Robert Charles Jahr | President, Chief Executive Officer & Director | USD 603.06K | 53 | 151.51K | 0.37% |
Greg DiPasquale | Chief Commercial Officer | USD 451.17K | — | — | — |
Jennifer Kissner | Senior Vice President of Clinical Development & Regulatory Affairs | — | — | — | — |
Jedd Comiskey | Senior Vice President - Head of Europe | — | — | — | — |
Kevin Lundquist | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | — | 58 | — | — |
Surendra Sharma | Senior Vice President of Medical Affairs | — | — | — | — |
Joel Prieve | Senior Vice President of Licensing and M&A | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 14, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
15
$18.22M
Sells
0
$0.00
Net Transaction Value
+$18.22M
Net buying
Most Active
Sukhtian Ghiath M.
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 14, 26Aug 14, 2026 | KENYON LAWRENCE A Direct | Buy | $100K$99,999.90 |
| Aug 14, 26Aug 14, 2026 | KENYON LAWRENCE A Direct | Buy | $111.1K$111,111.00 |
| Aug 14, 26Aug 14, 2026 | Jahr Robert Charles Direct | Buy | $150K$149,999.85 |
| Aug 14, 26Aug 14, 2026 | Jahr Robert Charles Direct | Buy | $166.7K$166,666.50 |
| Aug 12, 26Aug 12, 2026 | Sukhtian Ghiath M. Indirect | Buy | $2.5M$2,499,999.48 |
| Aug 12, 26Aug 12, 2026 | Sukhtian Ghiath M. Indirect | Buy | $2.8M$2,777,777.20 |
| Jul 29, 26Jul 29, 2026 | Sukhtian Faisal Ghiath Direct | Buy | $100K$99,996.18 |
| Jun 2, 26Jun 2, 2026 | Haddadin Yezan Munther Direct | Buy | $24.1K$24,145.40 |
| May 28, 26May 28, 2026 | Sukhtian Ghiath M. Indirect | Buy | $5M$4,999,999.62 |
| May 28, 26May 28, 2026 | Sukhtian Ghiath M. Indirect | Buy | $5M$5,018,571.09 |
1–10 of 15
Summary
Insiders reported 15 buys worth $18.22M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $18.22M. Sukhtian Ghiath M. was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +233.4% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +233.4% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Outlook Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about OTLK's management, answered from reported figures.
Who manages OTLK?
Outlook Therapeutics, Inc. (OTLK) lists 7 active executives. The top listed executive is Jennifer Kissner, Senior Vice President of Clinical Development & Regulatory Affairs.
Are OTLK insiders buying or selling?
Recent insider activity shows net buying of $137.50M.
Continue the stock analysis
Jump to another research area for this company.